Oncology Corporate Profile
Ignyta, Inc. is a trailblazing biotechnology company catalyzing personalized medicine in cancer. We are pursuing an integrated Rx/Dx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection. Our goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. We achieve this goal by leveraging our proprietary cancer and immunology genomic and epigenomic knowledge bases to discover novel targets and deliver the next generation of targeted therapeutics accompanied by highly informative biomarkers for patient selection, treatment, and monitoring.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|RXDX-105||multiple tyrosine kinase inhibitor||Various cancer types||II|
|entrectinib / RXDX-101||tyrosine kinase inhibitor||Various cancer types||II|
View additional information on product candidates here »